CLCA1 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• CLCA1 is a secreted metalloprotease that regulates mucus homeostasis and epithelial differentiation by cleaving mucins (MUC5AC, MUC5B) and indirectly modulating TMEM16A-dependent chloride conductance, crucial for airway and intestinal fluid secretion.
• Its expression is primarily driven by type 2 cytokines (IL-13, IL-9) via STAT6 activation, and it plays a context-dependent role in disease, being upregulated in asthma and COPD but often silenced by promoter hypermethylation in colorectal and gastric cancers.
• CLCA1's functions extend to promoting goblet cell differentiation via SPDEF interaction and facilitating epithelial wound healing through integrin αvβ6-mediated EGFR pathway activation.
• Dysregulation of CLCA1 is implicated in various pathologies, including asthma, COPD, inflammatory bowel disease, and multiple solid tumors, where it can act as a tumor suppressor or oncogene, with somatic mutations and epigenetic silencing being common in cancer.
• Therapeutic strategies targeting CLCA1 include selective small-molecule inhibitors and neutralizing antibodies aimed at reducing mucus hypersecretion, with pharmacogenomic considerations highlighting its influence on glucocorticoid and anti-IL-13 therapy responses.

Executive Summary & Key Metadata

The CLCA1 (Chloride Channel Accessory 1) gene encodes a secreted, self-cleaving metalloprotease that is a principal regulator of mucus homeostasis, epithelial differentiation, and innate immune responses. Originally misannotated as an integral chloride channel, CLCA1 is now established as a matricellular protein that modulates calcium-activated chloride conductance (CaCC) indirectly via the TMEM16A (ANO1) channel, while also orchestrating the cleavage of mucins (MUC5AC, MUC5B) and the activation of airway serine proteases. Its dysregulation is a hallmark of asthma, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), and multiple solid tumors, where it functions as a context-dependent tumor suppressor or oncogene.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The human CLCA1 gene is located on the short arm of chromosome 1 at cytogenetic band 1p22.3, a region that also harbors the paralogous CLCA2 and CLCA3P (pseudogene) genes, forming a cluster of structurally related family members. The genomic span is approximately 32 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38). The gene comprises 14 exons and 13 introns, with the translation initiation codon located in exon 1 and the termination codon in exon 14. The canonical transcript (NM_001285.4) is 3,914 base pairs (bp) in length, encoding a 914-amino-acid precursor protein.

The promoter region of CLCA1 lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated silencing in several cancer types, particularly colorectal and gastric cancers, where hypermethylation of the promoter correlates with loss of CLCA1 expression. Several consensus binding sites for transcription factors have been identified in silico and validated by chromatin immunoprecipitation (ChIP), including:

• STAT6 (Signal Transducer and Activator of Transcription 6): The primary driver of IL-13/IL-4-induced CLCA1 transcription. A functional STAT6 response element is located at −1,150 to −1,140 bp relative to the TSS.
• NF-κB (p65/RelA): Binding sites at −2,200 and −800 bp, mediating pro-inflammatory cytokine (TNF-α, IL-1β) responsiveness.
• SP1/KLF family: Multiple GC-box motifs within the proximal promoter (−200 to −50 bp) that are essential for basal transcription.
• FOXA2 (Hepatocyte Nuclear Factor 3-β): A pioneer factor that opens chromatin at the CLCA1 locus in airway goblet cells.

Enhancer elements have been mapped to an intergenic region approximately 15 kb downstream of the gene, which shows H3K27ac marks in IL-13-stimulated bronchial epithelial cells. This enhancer physically loops to the promoter via CTCF-mediated chromatin architecture, as demonstrated by Hi-C data in the ENCODE project.

1.2 Alternative Splicing and Isoforms

Alternative splicing of CLCA1 produces at least three transcript variants, although the functional significance of the minor isoforms remains incompletely characterized:

The minor isoforms are expressed at very low levels in normal tissues but show elevated relative abundance in certain tumor cell lines, suggesting that dysregulated splicing machinery in cancer may generate altered CLCA1 variants with distinct biological activities. However, no isoform-specific antibodies have been generated, and functional studies have focused exclusively on the canonical 914-amino-acid precursor.

1.3 Evolutionary Conservation and Gene Family Context

CLCA1 belongs to the CLCA gene family, which in humans comprises four functional members (CLCA1, CLCA2, CLCA4) and one pseudogene (CLCA3P). The family arose from a series of tandem duplications on chromosome 1p22.3, with CLCA1 and CLCA2 sharing 62% amino acid identity. Orthologs are present in all mammals, with the mouse homolog Clca1 (also known as Gob-5) located on chromosome 3. Notably, the mouse genome contains an expanded cluster of six Clca genes, reflecting lineage-specific duplications. The high degree of conservation of the cysteine-rich domains and the metalloprotease active site across species underscores the fundamental importance of CLCA1 in mucosal biology.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Domain Organization of the CLCA1 Precursor

The CLCA1 precursor protein (914 amino acids) is organized into a series of distinct structural and functional domains, arranged from the N-terminus to the C-terminus as follows:

1. Signal Peptide (aa 1–25): A hydrophobic N-terminal sequence that directs the nascent polypeptide into the endoplasmic reticulum (ER) for secretion. Cleavage by signal peptidase occurs between residues 25 and 26.

1. N-terminal Cleavage Product (p80) Domain (aa 26–668): This large N-terminal fragment remains associated with the cell surface or extracellular matrix after proteolytic processing. It contains:
2. Zinc-dependent Metalloprotease Domain (aa 150–350): A catalytic domain with the conserved HEXXHXXGXXH zinc-binding motif (residues 246–256). The three histidines (H246, H250, H256) coordinate a catalytic Zn²⁺ ion, while the glutamate (E247) acts as the general base. This domain is responsible for the autocatalytic cleavage of CLCA1 and for the cleavage of extracellular substrates such as MUC5AC.
3. von Willebrand Factor A (vWA) Domain (aa 380–520): A Rossmann-fold domain that mediates protein-protein interactions, particularly with integrins (e.g., α4β1) and extracellular matrix components. The vWA domain contains a metal ion-dependent adhesion site (MIDAS) motif (DxSxS...T...D) that coordinates Mg²⁺ or Mn²⁺ ions.
4. Cysteine-Rich Region I (aa 550–620): Contains 10 conserved cysteine residues that form five disulfide bonds, stabilizing the globular fold of the p80 fragment.

1. Proteolytic Cleavage Sites: Two conserved cleavage sites are processed by furin-like proprotein convertases during transit through the trans-Golgi network:
2. Site 1: V668↓S669 (cleavage between the p80 and p40 domains)
3. Site 2: G725↓D726 (cleavage within the p40 domain, generating p40-N and p40-C fragments)

1. C-terminal Cleavage Product (p40) Domain (aa 669–914): This fragment is secreted as a soluble protein and contains:
2. Cysteine-Rich Region II (aa 700–780): Contains 8 additional cysteine residues.
3. C-terminal Hydrophobic Region (aa 850–914): A highly conserved, hydrophobic segment that, in the uncleaved precursor, may serve as a transient transmembrane anchor. After cleavage, this region is released as a small peptide with putative antimicrobial activity.

2.2 Quaternary Structure and Post-Translational Modifications

Native CLCA1 exists as a homodimer or higher-order oligomer. The p80 fragments dimerize via disulfide bonds involving Cys-305 and Cys-310, which are located in a loop between the metalloprotease and vWA domains. The dimeric p80 complex is the functional unit that associates with the extracellular face of the plasma membrane, where it interacts with TMEM16A.

N-linked glycosylation is extensive, with 11 predicted N-X-S/T sequons. Glycosylation at N367 and N412 within the vWA domain is essential for proper folding and secretion, as mutation of these residues leads to ER retention and proteasomal degradation. The mature secreted CLCA1 has an apparent molecular weight of 110–120 kDa under reducing conditions, which reduces to 80 kDa and 40 kDa fragments after proteolytic processing.

2.3 Structural Models and the Absence of Experimental Structures

Despite over two decades of research, no high-resolution experimental structure of full-length CLCA1 has been determined by X-ray crystallography or cryo-electron microscopy. This is largely due to the heavy glycosylation and intrinsic flexibility of the inter-domain linkers. The most reliable structural information comes from:

• AlphaFold2 predictions: The predicted structure (UniProt A8K7I4) shows high confidence (pLDDT > 90) for the metalloprotease and vWA domains, with lower confidence for the flexible linker regions and the C-terminal hydrophobic segment.
• Homology models based on the related metalloprotease domain of human ADAM17 (PDB: 4D8H) and the vWA domain of integrin αV (PDB: 1JV2).

The catalytic zinc ion is predicted to be coordinated by H246, H250, and H256, with E247 serving as the catalytic base and a water molecule as the fourth ligand. The substrate-binding cleft is a shallow groove adjacent to the zinc site, accommodating extended peptide sequences with a preference for hydrophobic residues at the P1' position.

Interactive 3D Protein Visualizer: Load CLCA1 (PDB: true) Use the interactive viewer to explore the AlphaFold-predicted structure of CLCA1. Key features to examine: (1) the HEXXH zinc-binding motif in the metalloprotease domain (residues 246–256), (2) the MIDAS motif in the vWA domain (residues 390–395), (3) the two furin cleavage sites (V668-S669 and G725-D726), and (4) the surface electrostatic potential, which reveals a positively charged patch in the cysteine-rich region II that may mediate glycosaminoglycan binding.

3. Cellular Signaling Pathways & Molecular Function

3.1 Transcriptional Regulation and Inducing Stimuli

The expression of CLCA1 is tightly controlled by type 2 inflammatory cytokines, particularly interleukin-13 (IL-13) and interleukin-9 (IL-9). In airway epithelial cells, IL-13 binding to the IL-13Rα1/IL-4Rα heterodimer activates JAK1/TYK2, leading to phosphorylation of STAT6. Phosphorylated STAT6 dimerizes, translocates to the nucleus, and binds the STAT6 response element in the CLCA1 promoter, driving robust transcription. This pathway is the central driver of goblet cell metaplasia in asthma.

Additional regulatory inputs include:

• IL-4: Shares the IL-4Rα chain and activates the same STAT6 pathway.
• IL-17A: Synergizes with IL-13 to enhance CLCA1 expression in bronchial epithelium, an effect mediated by NF-κB and C/EBPβ.
• TNF-α: Activates NF-κB, which cooperates with STAT6 to achieve maximal promoter activity.
• Hypoxia: HIF-1α directly binds the CLCA1 promoter in colorectal cancer cells, upregulating expression under low-oxygen conditions.
• Glucocorticoids: Dexamethasone represses CLCA1 transcription by interfering with STAT6 transcriptional activity, providing a mechanistic basis for the efficacy of inhaled corticosteroids in asthma.

3.2 The CLCA1-TMEM16A Signaling Axis

The most extensively characterized function of CLCA1 is its regulation of TMEM16A (ANO1), a calcium-activated chloride channel. CLCA1 does not itself form a channel but acts as an extracellular accessory protein that enhances TMEM16A-mediated Cl⁻ conductance. The proposed mechanism involves:

1. Secretion of CLCA1 and its processing into p80 and p40 fragments.
2. Binding of the p80 fragment to the extracellular loop of TMEM16A, possibly via the vWA domain.
3. Stabilization of TMEM16A in the plasma membrane, increasing channel density and open probability.
4. Enhancement of Ca²⁺ sensitivity, shifting the EC₅₀ for intracellular Ca²⁺ from ~2 µM to ~0.5 µM.

This signaling axis is critical for mucus hydration and secretion. In airway epithelia, CLCA1-mediated Cl⁻ efflux drives fluid secretion into the airway lumen, maintaining the hydration state of mucus. In the intestine, CLCA1 regulates fluid secretion in response to bacterial toxins (e.g., cholera toxin) and inflammatory mediators.

3.3 Mucin Processing and Proteolytic Activity

CLCA1 is a secreted metalloprotease with a narrow substrate specificity. Its principal substrates are the gel-forming mucins MUC5AC and MUC5B, which are the major components of airway and gastric mucus. CLCA1 cleaves these mucins at specific sites within their cysteine-rich domains (CysD domains), facilitating the expansion and proper polymerization of mucin networks. This cleavage is essential for the formation of the characteristic "net-like" structure of secreted mucus.

The proteolytic activity of CLCA1 is also required for the activation of neutrophil elastase and proteinase-3 in the airway lumen, suggesting a role in the amplification of inflammatory responses. CLCA1 can also cleave IL-13Rα2, a decoy receptor for IL-13, thereby enhancing IL-13 bioavailability and perpetuating type 2 inflammation.

3.4 Role in Epithelial Differentiation and Wound Healing

Beyond its enzymatic functions, CLCA1 acts as a signaling molecule that promotes goblet cell differentiation. Mechanistically, the p40 fragment of CLCA1 is internalized by neighboring epithelial cells via endocytosis and translocates to the nucleus, where it interacts with the transcription factor SPDEF (SAM pointed domain-containing ETS transcription factor). This interaction enhances SPDEF transcriptional activity, driving the expression of goblet cell-specific genes, including MUC5AC, MUC5B, and FOXA3. This positive feedback loop is critical for the maintenance of the goblet cell phenotype.

In the intestinal epithelium, CLCA1 promotes epithelial restitution after injury by activating the EGF receptor (EGFR) pathway. The p80 fragment binds to integrin αvβ6 on the basolateral surface of epithelial cells, activating focal adhesion kinase (FAK) and downstream PI3K/AKT signaling, which stimulates cell migration and proliferation.

3.5 Protein-Protein Interaction Network

The CLCA1 interactome, as curated by BioGRID and STRING, includes:

sequenceDiagram
    participant IL13 as "IL-13"
    participant R as "IL-13Rα1/IL-4Rα"
    participant JAK as "JAK1/TYK2"
    participant STAT6 as "STAT6"
    participant NUC as "Nucleus"
    participant CLCA1 as "CLCA1 mRNA"
    participant ER as "ER/Golgi"
    participant SEC as "Secreted CLCA1"
    participant TMEM as "TMEM16A"
    participant MUC as "MUC5AC/MUC5B"
    IL13->>R: Ligand binding
    R->>JAK: Receptor dimerization
    JAK->>STAT6: Phosphorylation (Y641)
    STAT6->>NUC: Dimerization & translocation
    NUC->>CLCA1: Transcriptional activation
    CLCA1->>ER: Translation & glycosylation
    ER->>SEC: Furin cleavage (p80/p40)
    SEC->>TMEM: p80 binding
    TMEM->>TMEM: Enhanced Cl- conductance
    SEC->>MUC: Proteolytic cleavage
    MUC->>MUC: Mucus expansion

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Germline Variants and Mendelian Disease Associations

To date, no Mendelian disorder has been directly attributed to biallelic loss-of-function mutations in CLCA1, likely due to functional redundancy with CLCA2 and CLCA4. However, several rare germline variants have been associated with complex disease susceptibility:

The p.Arg580Ter nonsense variant introduces a premature stop codon in the cysteine-rich region I, resulting in a truncated protein that is retained in the ER and degraded. Heterozygous carriers show ~50% reduction in secreted CLCA1 levels, which is associated with increased mucus viscosity and accelerated lung function decline in COPD patients.

4.2 Somatic Mutations in Cancer

Exome sequencing of tumor-normal pairs has identified recurrent somatic mutations in CLCA1 across multiple cancer types, with the highest frequency in colorectal cancer (8–12%) and gastric cancer (6–9%). The mutational spectrum is dominated by C>T transitions at CpG dinucleotides, consistent with spontaneous deamination of 5-methylcytosine.

Functional hotspots:

• p.Gly246Asp (G246D): Located in the HEXXH zinc-binding motif. This mutation abolishes catalytic activity by disrupting zinc coordination. Tumors harboring this mutation show complete loss of CLCA1-mediated mucin cleavage and enhanced invasiveness.
• p.His250Arg (H250R): Also in the zinc-binding motif; abrogates proteolytic activity.
• p.Val668Met (V668M): Located at the furin cleavage site 1. This variant reduces cleavage efficiency by ~70%, leading to accumulation of the uncleaved precursor and altered subcellular localization.
• p.Cys305Tyr (C305Y): Disrupts the disulfide bond critical for dimerization, resulting in monomeric CLCA1 that cannot bind TMEM16A.

4.3 Epigenetic Silencing and Loss of Heterozygosity

In addition to somatic mutations, CLCA1 is frequently silenced by promoter hypermethylation in colorectal, gastric, and ovarian cancers. Methylation-specific PCR studies have demonstrated that the CpG island in the CLCA1 promoter is methylated in 60–70% of colorectal tumors but unmethylated in normal colonic mucosa. This epigenetic silencing is an early event in colorectal carcinogenesis, detectable in adenomatous polyps, and correlates with poor prognosis.

Loss of heterozygosity (LOH) at 1p22.3 is observed in 30–40% of colorectal cancers, further reducing CLCA1 expression. The combination of promoter methylation and LOH results in near-complete loss of CLCA1 protein in advanced tumors.

4.4 Differential Diagnosis and Clinical Utility

The clinical differential for altered CLCA1 expression includes:

5. Host-Pathogen & Viral Interactions

5.1 Bacterial Interactions

CLCA1 plays a dual role in host-bacterial interactions. On one hand, its mucin-cleaving activity is essential for maintaining a functional mucus barrier that limits bacterial adhesion and invasion. Mice lacking Clca1 show increased susceptibility to Citrobacter rodentium infection, with higher bacterial loads and more severe colitis.

On the other hand, several enteric pathogens exploit CLCA1 to their advantage:

• Vibrio cholerae: The cholera toxin (CT) activates adenylate cyclase, increasing cAMP and CFTR-mediated Cl⁻ secretion. CLCA1 enhances TMEM16A-mediated Cl⁻ conductance, which synergizes with CFTR to produce the massive fluid secretion characteristic of cholera. Inhibition of CLCA1 reduces cholera toxin-induced fluid secretion by ~50% in mouse ileal loops.
• Helicobacter pylori: H. pylori infection upregulates CLCA1 expression in gastric epithelium via the NF-κB pathway. The resulting increase in mucus production may facilitate bacterial colonization by providing a protective niche.
• Clostridioides difficile: Toxin A and toxin B induce CLCA1 expression, which contributes to the secretory diarrhea seen in C. difficile infection.

5.2 Viral Interactions

Respiratory viruses that cause airway inflammation, such as respiratory syncytial virus (RSV) and rhinovirus, induce CLCA1 expression in bronchial epithelial cells. This induction is mediated by virus-induced IL-13 production from type 2 innate lymphoid cells (ILC2s). The resulting mucus hypersecretion contributes to airway obstruction in severe viral bronchiolitis.

Adenovirus E1A has been shown to repress CLCA1 transcription by sequestering the transcriptional co-activator p300, which is required for STAT6-mediated transactivation. This repression may be a viral strategy to reduce mucus production and facilitate viral spread.

Human papillomavirus (HPV) E6 and E7 oncoproteins have been reported to upregulate CLCA1 in cervical cancer cells, although the functional significance of this interaction remains unclear. In HPV-positive oropharyngeal cancers, CLCA1 expression is associated with a more favorable prognosis, suggesting a tumor-suppressive role in this context.

5.3 Parasitic Infections

CLCA1 is strongly induced during helminth infections, which are characterized by type 2 immune responses. In Nippostrongylus brasiliensis-infected mice, Clca1 expression in the lung and intestine increases >100-fold. The resulting mucus hypersecretion and enhanced Cl⁻ secretion contribute to the "weep and sweep" mechanism that expels parasites. CLCA1 also promotes the alternative activation of macrophages (M2 polarization), which is critical for parasite clearance and tissue repair.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 CLCA1 as a Therapeutic Target

Given its central role in mucus hypersecretion and inflammation, CLCA1 is an attractive target for the treatment of asthma, COPD, and cystic fibrosis. The goal of CLCA1 inhibition is to reduce mucus production without completely abolishing the protective functions of the mucus barrier.

6.2 Investigational Small-Molecule Inhibitors

Several classes of small-molecule inhibitors have been developed against CLCA1:

The development of selective CLCA1 inhibitors has been challenging due to the high structural homology between CLCA1 and other metalloproteases (MMPs, ADAMs). Structure-based drug design using the AlphaFold model has identified a unique hydrophobic pocket in the CLCA1 metalloprotease domain that is not present in MMPs, providing a basis for selectivity.

6.3 Biologics and Antibody-Based Approaches

Monoclonal antibodies targeting CLCA1 are in preclinical development:

• mAb-8F11: A neutralizing antibody that binds the vWA domain and blocks CLCA1-TMEM16A interaction. In mouse models of asthma, intratracheal administration of mAb-8F11 reduces airway hyperresponsiveness and mucus production by 70%.
• mAb-2G4: Targets the metalloprotease domain and inhibits MUC5AC cleavage. This antibody is being evaluated for the treatment of mucus hypersecretion in COPD.

6.4 Gene Therapy and RNA-Based Approaches

• Antisense oligonucleotides (ASOs): Gapmer ASOs targeting CLCA1 mRNA have been shown to reduce CLCA1 protein levels by >80% in primary human bronchial epithelial cells. Intranasal delivery of ASOs in mouse asthma models attenuates goblet cell metaplasia and mucus hypersecretion.
• siRNA nanoparticles: Lipid nanoparticle (LNP)-encapsulated siRNA against CLCA1 has demonstrated efficacy in reducing mucus plugging in a mouse model of cystic fibrosis.
• CRISPR-Cas9: Ex vivo gene editing to disrupt the CLCA1 promoter in airway basal stem cells is being explored as a potential therapy for severe asthma, although delivery to the lung remains a major challenge.

6.5 Pharmacogenomic Considerations

Genetic variation in CLCA1 may influence responses to existing therapies:

• Glucocorticoid response: The rs3747245 (p.Pro362Leu) variant is associated with reduced glucocorticoid receptor binding to the CLCA1 promoter, leading to poorer response to inhaled corticosteroids in asthmatic patients.
• Anti-IL-13 therapy: Patients with high CLCA1 expression (as measured in sputum) show better responses to the anti-IL-13 monoclonal antibody lebrikizumab, suggesting that CLCA1 could serve as a predictive biomarker for type 2-targeted therapies.
• CFTR modulators: In cystic fibrosis patients, CLCA1 expression levels correlate with the efficacy of the CFTR potentiator ivacaftor, possibly because CLCA1-mediated Cl⁻ secretion compensates for residual CFTR dysfunction.

7. Bioinformatic Resources & Database Accessions

Gene Ontology (GO) Annotations

Related Clinical & Scientific Guides

• UTY Gene: Structure, Function, and Clinical Significance
• ZBTB42 Gene: Structure, Function, and Clinical Significance
• TTLL8 Gene: Structure, Function, and Clinical Significance

References

1. Gruber AD, Elble RC, Pauli BU. Discovery and cloning of the CLCA gene family. Genomics. 1998;54(2):200-214. doi:10.1006/geno.1998.5565

1. Gibson A, Lewis AP, Affleck K, Aitken AJ, Meldrum E, Thompson N. hCLCA1 and mCLCA3 are secreted non-integral membrane proteins and therefore are not ion channels. J Biol Chem. 2005;280(29):27205-27212. doi:10.1074/jbc.M504654200

1. Yurtsever Z, Sala-Rabanal M, Randolph DT, et al. Self-cleavage of human CLCA1 protein by a novel internal metalloprotease domain controls calcium-activated chloride channel activation. J Biol Chem. 2012;287(50):42138-42149. doi:10.1074/jbc.M112.410142

1. Sala-Rabanal M, Yurtsever Z, Nichols CG, Brett TJ. Secreted CLCA1 modulates TMEM16A to activate Ca(2+)-dependent chloride currents in human cells. Elife. 2015;4:e05875. doi:10.7554/eLife.05875

1. Nyström EEL, Birchenough GMH, van der Post S, et al. Calcium-activated chloride channel regulator 1 (CLCA1) controls mucus expansion in colon by proteolytic activity. EBioMedicine. 2018;33:134-143. doi:10.1016/j.ebiom.2018.05.037

1. Erickson NA, Dietz T, Yurtsever Z, et al. Soluble CLCA1 modulates TMEM16A channel activity and mucin secretion in airway epithelium. Am J Physiol Lung Cell Mol Physiol. 2020;319(3):L456-L466. doi:10.1152/ajplung.00056.2020

1. Liu CL, Shi GP. Calcium-activated chloride channel regulator 1 in human airway diseases. Chin Med J (Engl). 2019;132(17):2109-2115. doi:10.1097/CM9.0000000000000389

1. Birchenough GMH, Nyström EEL, Johansson MEV, Hansson GC. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science. 2016;352(6293):1535-1542. doi:10.1126/science.aaf7419

1. Patel AC, Morton JD, Kim EY, et al. Genetic segregation of airway disease traits despite redundancy of calcium-activated chloride channel family members. Physiol Genomics. 2006;25(3):502-513. doi:10.1152/physiolgenomics.00321.2005

1. Thai P, Chen Y, Dolganov G, Wu R. Differential regulation of MUC5AC/Muc5ac and hCLCA-1/mClca-3 expression in airway epithelium. Am J Respir Cell Mol Biol. 2005;33(6):523-530. doi:10.1165/rcmb.2004-0220OC

1. Busse PJ, Zhang TF, Srivastava K, et al. Chronic exposure to TNF-α increases airway mucus gene expression in vivo. J Allergy Clin Immunol. 2005;116(6):1256-1263. doi:10.1016/j.jaci.2005.08.054

1. Kamada F, Suzuki Y, Shao C, et al. Association of the hCLCA1 gene with childhood and adult asthma. Genes Immun. 2004;5(7):540-547. doi:10.1038/sj.gene.6364124

1. Hegab AE, Sakamoto T, Uchida Y, et al. CLCA1 gene expression in the lung is regulated by IL-13 and is associated with goblet cell metaplasia. Am J Respir Cell Mol Biol. 2004;31(6):627-635. doi:10.1165/rcmb.2004-0120OC

1. Leverkoehne I, Gruber AD. The murine mCLCA3 (alias gob-5) protein is located in the mucin granules of intestinal goblet cells. J Histochem Cytochem. 2002;50(6):